文献速递类风湿关节炎

伊布司特抑制类风湿关节炎滑膜成纤维细胞趋化因子表达并在实验性关节炎中显示免疫调节活性

Ibudilast Inhibits Chemokine Expression in Rheumatoid Arthritis Synovial Fibroblasts and Exhibits Immunomodulatory Activity in Experimental Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2019-04-12

本研究评估PDE4抑制剂伊布司特对活化人白细胞和类风湿关节炎滑膜成纤维细胞(RASFs)炎症介质表达的影响,并在胶原诱导性关节炎小鼠模型中观察其治疗作用。结果显示伊布司特抑制TNF、IL12A、IL12B表达及TNF和IL-12/23p40分泌,减少RASFs中CCL5和CCL3表达,在体内减少IL-17产生细胞并抑制疾病进展,与TNF抑制剂联用显著抑制活动性疾病。

要点

  • 伊布司特抑制活化白细胞TNF、IL12A、IL12B表达及TNF、IL-12/23p40分泌。
  • 伊布司特减少活化RASFs中CCL5和CCL3表达。
  • 伊布司特在实验性关节炎中减少IL-17产生细胞并抑制疾病进展,与TNF抑制剂联用效果显著。

核心结论

  • 伊布司特可减少活化人白细胞和RASFs炎症介质的表达和/或分泌,在体内抑制Th17细胞反应并改善已建立的关节炎。

研究设计与样本

  • 使用标准曲线定量PCR测量伊布司特对活化人白细胞和RASFs基因表达的影响。
  • 用伊布司特治疗DBA/1小鼠胶原诱导性关节炎,并采用过继转移模型评估其免疫耐受能力。

主要发现

  • 伊布司特抑制白细胞TNF、IL12A、IL12B表达及TNF和IL-12/23p40分泌。
  • 伊布司特减少活化RASFs中CCL5和CCL3表达。
  • 伊布司特治疗实验性关节炎减少IL-17产生细胞并抑制疾病进展。
  • 伊布司特与TNF抑制剂联用显著抑制活动性疾病。
  • II型胶原免疫DBA/1小鼠白细胞体外暴露伊布司特后,其过继转移关节炎至DBA/1J-PrkdcSCID小鼠的能力减弱。

临床怎么用

  • 鉴于伊布司特在人体已确立的安全性,应考虑在RA中单独或与TNF抑制剂联合进行临床评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Ibudilast is a well-tolerated, orally available phosphodiesterase 4 (PDE4) inhibitor used to treat asthma and stroke. Since PDE4 inhibition suppresses inflammatory mediator production and cell proliferation in leukocytes, ibudilast may be a valuable therapy for the treatment of inflammatory autoimmune diseases such as rheumatoid arthritis (RA). This study was undertaken to assess the therapeutic potential of ibudilast by measuring its capacity to modulate inflammation in human leukocytes and RA synovial fibroblasts (RASFs) and in experimental arthritis. METHODS: Using standard curve quantitative polymerase chain reaction, the effect of ibudilast on gene expression in activated human leukocytes and RASFs was measured. Ibudilast was used to treat DBA/1 mice with collagen-induced arthritis, and an adoptive transfer model was used to assess its tolerogenic capacity. RESULTS: Ibudilast inhibited the expression of TNF, IL12A, and IL12B and the secretion of tumor necrosis factor (TNF) and interleukin-12 (IL-12)/23p40 from leukocytes, and reduced the expression of CCL5 and CCL3 in activated RASFs. Treatment of experimental arthritis with ibudilast resulted in a reduction in IL-17-producing cells and inhibition of disease progression. When combined with a TNF inhibitor, ibudilast caused marked suppression of active disease. Exposure of leukocytes from type II collagen-immunized DBA/1 mice to ibudilast in vitro attenuated their ability to adoptively transfer arthritis to DBA/1J-PrkdcSCID mice, providing evidence of an immunomodulatory effect. CONCLUSION: Our findings indicate that ibudilast reduces the expression and/or secretion of inflammatory mediators from activated human leukocytes and RASFs, inhibits Th17 cell responses in vivo, and improves established arthritis. Given the established safety profile of ibudilast in humans, its clinical evaluation in RA, either alone or in combination with a TNF inhibitor, should be considered.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Clanchy FIL, Williams RO. Ibudilast Inhibits Chemokine Expression in Rheumatoid Arthritis Synovial Fibroblasts and Exhibits Immunomodulatory Activity in Experimental Arthritis. Arthritis Rheumatol. 2019. PMID: 30474934. doi:10.1002/art.40787

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。